Help Close the Biggest Diagnostic Gap in Healthcare
We have broad patents covering AI-ECGs. This technology will give doctors and nurses the ability to detect heart disease, the world’s leading cause of death, much earlier. With Mayo Clinic as an early AI-ECG adopter and Medicare reimbursement already confirmed starting January 2025, now’s your chance to invest before FDA submission and full-scale commercialization begins, which could see the share price skyrocket.
Unit Price
$675
Min. Investment
150+
Investors
: HSCS
Why You Could Get More by Investing in This Offering
When you invest through our current offering, you get an investment unit that comes with:
1 Share of Convertible Preferred Stock (convertible into Nasdaq freely tradable common stock at anytime)
1 Warrant to purchase an additional share of Nasdaq tradable common stock at a fixed price exercisable at anytime for three years
That’s 2 shares of equity potential per unit at $3.50, offering potentially significantly more upside than buying a single share of common stock on the open market. This highly attractive structure has been designed to give investors maximum flexibility and potential long-term value.
500% Return Potential with Preferred Share + Warrant
Our stock has been rated a “Strong Buy” on Yahoo! Finance—the average analysts price target is 270% upside from a $3.50 common stock price . As detailed below, this investment opportunity gives nearly 2X that potential.
The World’s #1 Cause of Death
ECGs are used ~1 billion times per year to detect heart disease. It’s the frontline test to detect heart disease due to its ease, low cost, and doesn’t require a specialist. But they generally only detect rhythm-related issues, like arrhythmia or AFib. By then, a patient often has late-stage heart disease. Earlier detection for the general population could save countless lives.
AI-Powered ECG for Earlier Detection
Our software platform and AI-powered mobile devices enable the detection of heart disease that may have previously been hidden from standard ECGs.
A weak heart pump
Blocked arteries
Heart valve problems
Enlarged heart
General heart (cardiac) dysfunction
Comprehensive AI-ECG Solutions for anyCare Environment:
MyoVista® wavECG™ Device:
One device using embedded AI, one comprehensive test providing both conventional and AI-ECG results. Designed as a simple test to provide immediate results in a next to patient point-of-care environment.
MyoVista Insights™ Cloud Platform:
A cybersecure software solution that provides AI-ECG results using existing ECG devices. Designed for major hospital systems worldwide to plug into their existing IT systems without the need to change out device hardware.
Validated by the Biggest Names in Medicine
Our software solution, AI-ECG algorithms and first-of-its-kind AI-enhanced ECG device are more than a big idea. They’re developed with or proven in trials across a broad range of institutions around the world including Mount Sinai in NY, Rutgers University Hospital, the U.K. NHS, Denmark, Australia, India and Ireland. Mayo Clinic is an early adopter of AI-ECG and:
CPT codes are already in place
Medicare is reimbursing as of January 2025
We are targeting FDA approval this year
All of this dramatically de-risks HeartSciences our innovation as we move to commercialize.
Icahn School of Medicine at Mount Sinai, New York, a world leading cardiology hospital is our largest shareholder and licensed its AI-ECG IP to HeartSciences.
Long standing collaboration with Rutgers Robert Wood Johnson Hospital System, New Jersey.
Beta use and key opinion leader engagement in many European countries.
MyoVista® wavECG™ recently selected for demonstration at the United Nations General Assembly Digital Health Symposium as a technology to radically transform healthcare.
"Learn how Rutgers' Innovation Center is leveraging our technology to drive clinical advancements and shape the future of cardiac care."
Company Updates
A Potential $30B Revolution in Cardiac Diagnostics
The global ECG market is projected to reach $30B by 2034. And with millions of ECGs performed globally every day, demand for advanced diagnostic tools like our AI-ECGs is accelerating rapidly.
Over 100 million ECGs are performed annually in the U.S. alone; ~1B worldwide.
Medicare has already agreed a $128 AI-ECG reimbursement rate which is on top of the ~$60 rate for traditional ECGs.
Potential for more than $10M in additional annual billing from just a single AI-ECG algorithm in a large health system.
Diagnostic Gap: Most patients are asymptomatic.
Lack of low cost effective tools
Few tests can be administered in clinic
Payors resist expensive tests for asymptomatic patients
High cost effective tools
Echocardiogram
Nuclear Stress Test
CT Angiogram
Invasive Angiogram
We are filling this gap.
FDA Clearance and Revenue on Our 2025 Agenda
After several years and over $70 million invested during R&D, FDA submissions and approvals are anticipated in the near term. We expect first FDA approval by the end of the year, opening up the entire US market for us. Our plan for 2025 is designed to drive growth, expand market reach, and work to revolutionize cardiovascular diagnostics worldwide.
Phase 1
Cloud-Native ECG Reporting Platform (Completed in 2024)
Create a modern, secure ECG reporting system running on AWS.
Cybersecure, cloud-native architecture to replace outdated, on-premise systems.
Phase 2
AI-ECG Integration and Marketplace (FDA Submission in H2 2025)
Add AI-powered ECG reporting to the platform.
Support for HeartSciences’ proprietary and third-party AI-ECG algorithms via a marketplace model (like an "app store").
Reduce costs and accelerate adoption of AI-ECG solutions across healthcare settings.
Phase 3
Comprehensive ECG Management System (2026 and Beyond)
Launch a fully modern ECG management system addressing global healthcare needs.
Replace legacy ECG IT systems with a flexible, cost-effective, and cybersecure cloud solution.
Potential to expand use cases to include remote care, such as home-based monitoring and telehealth.
Preclinical R&D
Presubmission
Clinical Trials
Submission & Approval
Why Smart Investors Choose HSCS Investment Units Over Common Stock
Each $3.50 unit is exclusively available through our Reg A+ round includes one convertible preferred share and one warrant to purchase an additional share of common stock - that’s two shares of Nasdaq tradeable common stock equity potential per unit, with the added benefit of preferred stock protections until you want to convert and timing flexibility on the warrant. It’s an investment structure typically reserved for institutional insiders—but available to everyday investors in this offering.
It’s a strategic opportunity to get more equity, more possible upside, and more control compared to buying on the market.
HeartSciences has been rated a “Strong Buy” on Yahoo Finance, with the average analysts price target being 270% upside to a $3.50 common stock price.
As shown below, Investors who act through our Reg A+ offering could unlock up to 500% potential return—nearly 2X based on the analyst price forecasts.
AI-Powered Cardiac Care
Meet the visionary leaders shaping the future of heart disease detection and prevention.
Extensive experience as CEO and Director of public and private companies managing multi-billion-dollar assets and leading innovative ventures.
Serial entrepreneur with a track record of building and selling technology companies.
Certified Public Accountant with over 15 years of experience in financial reporting and compliance.
Over 25 years in engineering and product development for cardiac devices.
Expert in FDA submissions and regulatory affairs for medical devices
FAQs
What Is the Unit Priced At?
The public offering price of the Unit is $3.50. Each investment unit includes:
✔ 1 Convertible Preferred Share (convertible into 1 Common Share)
✔ 1 Common Stock Warrant (allowing the purchase of 1 more share of Common Stock at a fixed price)
Are the Units Registered Securities?
The Common Stock receivable following conversion of the Preferred Shares, or exercise of the warrants, have been registered and could be traded immediately.
Will the Preferred Shares Trade?
The Preferred Shares do not trade, but each Preferred Share is convertible at any
time into one share of Common Stock that trades on Nasdaq under the symbol
“HSCS”. The Common Stock has been registered, so it would be immediately tradable
following conversion.
What Is a Warrant?
A warrant is a financial instrument that gives the holder the right—but not the obligation—to purchase our company's stock at a $5.00 strike price for three years. Stock warrants are often used by companies to raise capital or sweeten deals for investors, as they allow investors to get extra shares at a fixed price and leverage potential stock price increases.
Do I Have to Be An Accredited Investor to Purchase Units?
No, you do not need to be an accredited investor.
What Is the Minimum Investment Amount?
The minimum investment amount is $675, or 193 Units.
Where Are My Shares Held?
Your shares and warrants are held in book-entry (electronic) format directly with the transfer agent. You will not receive a stock certificate, but you will receive a statement showing your ownership.
Can the Company Force Conversion of the Preferred Shares?
Upon the occurrence of any of the following events, the Company shall have a right to direct the mandatory conversion of the Series D Preferred Stock: (a) a change in control of our Company, (b) if the price of the Common Stock closes at or above $5.00 per share for 10 consecutive trading days, or (c) if we consummate a firm commitment public offering of Common Stock for gross proceeds of at least $15 million at an offering price per share equal to or greater than $5.00.
How Do the Shares and Warrants Convert to Common Stock?
Each share of the Preferred is convertible into one share of Common Stock at any time at the holder’s option. Each warrant can be exercised into 1 share of Common Stock at $5.00. All you need to do is notify the transfer agent you wish to convert your shares or exercise your warrants and you can transfer and trade with your broker.
If the Common Stock Is Above $3.50, What Happens?
You can convert your Preferred Stock into Common Stock at any time and, if you choose, have your broker sell it—capturing the difference between the sale price and $3.50. Once you convert, you will still retain your warrant.
How Do I Pay for the Shares?
After you complete the subscription by clicking “Invest Now,” you may pay the escrow agent by credit card, wire transfer, or ACH transfer.
How Long Do I Have to Wait to Sell My Shares After I Purchase?
Shares in the offering are eligible for resale immediately; however, you may initially only transfer those shares that have been converted from Preferred to Common Stock.
How Do I Transfer My Shares to My Broker to Trade?
Once you convert to Common Stock, you can easily transfer your shares to your broker. You will not be able to transfer the Preferred Shares, but you may convert them at any time. There is no cost or annual fee to keep your shares with Equiniti Trust Company, LLC if you prefer not to move them to a brokerage.
How Do I Purchase the Company’s Common Stock Now?
You can purchase shares directly through your broker. The Company is listed on NASDAQ under the symbol HSCS.
Who Is the Company’s Independent Auditor?
Haskell & White LLP
Website: https://www.hwcpa.com/
How Do I Contact HSCS Investor Relations?
Integrous Communications
Mark Komonoski, Partner
Phone: 877-255-8483
Email: mkomonoski@integcom.us
What Is a Transfer Agent?
A transfer agent maintains a record of ownership, including contact information for shareholders.
Who Is the Company’s Transfer Agent?
Equiniti Trust Company, LLC (formerly AST)
Website: https://equiniti.com/us/ast-access
Phone: 1-800-937-5449 (toll free) or 1-718-921-8124
Email: HelpAST@equiniti.com
How Do I Get Additional Information on the Offering?
For more details, please read the Form 1-A here in its entirety.
What kind of shares are you issuing?
The Company is offering, on a “best efforts’ basis, up to 4,285,714 Units, each Unit consisting of one (1) share of Series D Convertible Preferred Stock and one (1) warrant to purchase common stock. The Units will be sold at an offering price of $3.50 per Unit. The warrants are exercisable at a price of $5.00 for one (1) share of Common Stock.
Where can I find the company’s SEC filings?
All of HeartSciences’ regulatory filings, including financial reports, can be found here:
How much are you raising?
The Units will be sold at an offering price of $3.50 per Unit, for a maximum offering amount of $15,000,000.
How will I get a return on my investment?
Investing in startups is risky and there is no guarantee you will get a return on your investment. However, the fact that our common stock is listed on Nasdaq (Nasdaq: HSCS) opens up an opportunity for you to convert your preferred shares into common stock providing an exit in cash (if you choose to sell the common stock) or desire to hold a more liquid asset. If the value of our Company grows, then you have a higher potential of making a profit on your investment.You are investing in a pre-revenue company selling an emerging technology. Success will be measured in progress towards commercialization and growing revenue and profitability.
When will I receive my shares?
Shares will be issued through the transfer agent, Equiniti Trust Company, LLC after the investment funds clear.
Are there higher fees if you invest via credit card vs. ACH?
No, costs are the same, regardless of how you invest.
How Will I (Investor) Make Money?
The Company expects to achieve many milestones in 2025, including FDA clearance which would be expected to see an increase in our share price. We are already listed on Nasdaq so there is the ability to buy and sell our Common Stock. Additionally, the warrants offer the ability to buy further shares at a fixed price.
How Do I Know People Will Buy This Solution?
The FDA has already created a new clinical pathway specifically for AI-ECG, the American Medical Association issued new reimbursement codes and in early 2025 Medicare agreed to start paying for use of AI-ECG. Mayo Clinic is expected to be one of the early adopters and has already used the reimbursement code for AI-ECG tens of thousands of times.
Are There More Opportunities Ahead?
We are at the beginning of what is expected to be a new era for an ECG and its clinical capabilities and we expect many new opportunities. We would expect to bring a portfolio of valuable algorithms into clinical practice and have plans to roll-out further upgrades for both the MyoVista wavECG device and MyoVista Insights cloud-platform. We also have a number of international opportunities and relationships.
Why Didn't A Bigger Company Do This Already?
The big companies tend to focus on maximizing sales of existing products rather than innovation of new ones. Additionally, the data required to develop new algorithms is held by clinical institutions rather than companies and is a barrier to entry and why our clinical collaborations and partnerships in this field are valuable.
How do you plan to use the proceeds from this funding round?
Proceeds from this offering will be used to fund the Company achieving regulatory clearances for its products as well as on-going R&D and clinical activities, sales and marketing and general corporate purposes.
What is the current valuation of the Company?
Based on the $3.50 conversion price the pre-money valuation is $4 million.
Why Should I Invest?
Your support and commitment will help HeartSciences shape the future of heart healthcare and early detection of heart disease.
How long are you expecting the company to operate before needing another round?
If we are able to raise the full amount it is anticipated that this will allow us to get our first products to market. We would expect to need additional capital at that time to market and sell the product.
What is the exit plan for the company?
We are a Nasdaq listed company. Investors can convert their Preferred Stock to Common Stock and are free to trade it at any time. We also anticipate that as we get into sales the Company may well be attractive for acquisition by a larger medical devices company.
What markets are you currently focused on?
We are a medical technology company focused on making the ECG (also known as an EKG) significantly more clinically valuable so that it can detect heart disease earlier. The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.
How many investors do you have already?
We are a listed company with over 3,000 holders of our common stock.
Will you be paying out dividends to investors?
We do not intend to pay dividends in the near future.
What is HeartSciences’ core business?
HeartSciences is focussed on making the ECG (also known as an EKG) far more clinically valuable so that so that it can detect heart disease earlier. We are developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.
Where are your headquarters located?
Southlake, Texas
How many employees does your Company have?
15
When will the Company expand into additional markets and which ones?
In addition to the USA, we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets.
Do you plan to expand internationally?
Yes we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets. We intend to market our products in those areas regulatory clearances.
Can you share the roadmap for the next 3-4 years and when you expect to become profitable?
Our business model is based on valuable recurring revenues charging a fee for single use supplies, use of algorithms and/or a SaaS subscription which are all at high margin. We expect revenue to start in 2026 and increase substantially as products are adopted and there is an installed user base. Today, more than 100 million ECG tests are performed in the US alone and accordingly, we expect to become profitable much earlier than most medical device companies.
Do you plan on licensing your technology?
Yes, that is one of several potential revenue streams.
How many patents do you have?
43 patents.
What does your path to profitability look like?
See #18 above
Who are your competitors? What are your advantages against them?
The traditional ECG market is dominated by large medical device manufacturers like GE Healthcare. However, traditional ECGs are decades old technology. AI-ECG is a fast emerging new field with a handful of early stage companies. We have been around longer and have significantly greater experience and relationships in this field than most other companies. We are the only company developing holistic device and cloud-native device agnostic AI-ECG solutions which will enable us to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services
Who is the main audience target for your product/service?
The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.
Are you looking to partner with other companies?
We are already partnering with several healthcare institutions and overtime see enormous opportunities for partnering with other companies. Either alternative/ telehealth ECG hardware (such as the Apple watch) or the MyoVista Insights platform providing an AI-ECG marketplace to host third party algorithms.
What have been the main challenges in developing your service/product and how have they been mitigated?
The development of AI-ECG algorithms requires access to significant health care data. We have collaborated with many healthcare institutions such in the US, the UK, Denmark and Australia and licenced considerable IP from Mount Sinai, New York which is one of the world’s leading cardiology healthcare institutions.